A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

NCT07137338 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Dilated Cardiomyopathy (DCM)

Interventions

GENETIC: RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)

Sponsor

Rocket Pharmaceuticals Inc.